The objective of this report is to discuss the potential for normal hormone regulation and application of chronic phosphodiesterase type 5 inhibition for the management of recurrent ischemic priapism. A 64-year-old man presented with refractory priapism treated with antiandrogen therapy. He was transitioned to and well controlled on a regimen of daily phosphodiesterase type 5 inhibitor and every other week antiandrogen therapy. Our treatment of recurrent priapism implicates androgens and both biochemical and neurovascular control mechanisms in the penis.
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Reproductive Medicine